# US 10,864,256 B2 · Methods and compositions for improved cognition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,256 B2
- Document ID: US10864256B2
- Status: Granted
- Kind: B2
- Application number: 16/751,108
- Filed: 2020-01-23
- Published: 2020-07-23
- Granted: 2020-12-15
- Earliest claimed: 2015-02-06
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Dena Dubal
- Web page: https://patentgrep.com/patent/US10864256B2

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12Y 302/01031: Beta-glucuronidase (3.2.1.31)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.

## Claims

### Claim 1

A method of treating cognitive decline in an individual having a mental or mood disorder, comprising administering systemically to the individual an effective amount of a recombinant polypeptide comprising an amino acid sequence having at least 95% identity to the sequence of amino acids 34-979 of SEQ ID NO:1, with the proviso that the polypeptide is not a FGF fusion protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the individual's mental or mood disorder is depression, schizophrenia, attention deficit/hyperactivity disorder, autism spectrum disorder, or intellectual disability.

### Claim 3 (depends on 2)

The method of claim 2, wherein the individual's mental or mood disorder is depression.

### Claim 4 (depends on 2)

The method of claim 2, wherein the individual's mental or mood disorder is schizophrenia.

### Claim 5 (depends on 2)

The method of claim 2, wherein the individual's mental or mood disorder is attention deficit/hyperactivity disorder.

### Claim 6 (depends on 2)

The method of claim 2, wherein the individual's mental or mood disorder is autism spectrum disorder.

### Claim 7 (depends on 2)

The method of claim 2, wherein the individual's mental or mood disorder is intellectual disability.

### Claim 8 (depends on 1)

The method of claim 1, wherein the amino acid sequence is at least 99% identical to amino acids 34-979 of SEQ ID NO:1.

### Claim 9 (depends on 1)

The method of claim 1, wherein the amino acid sequence comprises amino acids 34-979 of SEQ ID NO:1.

### Claim 10 (depends on 1)

The method of claim 1, comprising:
determining cognitive function in the subject before administration of the polypeptide,
determining cognitive function in the subject following systemic administration of the polypeptide, and
comparing the cognitive function in the subject before administration of the klotho to the cognitive function of the subject following administration of the polypeptide.

### Claim 11 (depends on 1)

The method of claim 1, wherein the polypeptide is administered to the subject intravenously.